KYMR vs. MEDP: Kymera Therapeutics vs. Medpace Stock Comparison

November 11, 2026

How do Kymera Therapeutics (KYMR) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.

Company profile comparison for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Profile Item	KYMR	MEDP
Name	Kymera Therapeutics Inc.	Medpace Holdings, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	11.25 billion USD	18.27 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 21, 2020	August 11, 2016
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

KYMR

MEDP

GSPC

Kymera Therapeutics (KYMR) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Kymera Therapeutics (KYMR) and Medpace (MEDP). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Kymera Therapeutics (KYMR) and Medpace (MEDP). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Total Return (1Y)	131.52%	13.29%
Total Return (3Y, Annualized)	111.65%	35.26%
Total Return (5Y, Annualized)	15.68%	24.49%

Risk Profile

Drawdown History

KYMR

MEDP

GSPC

Kymera Therapeutics (KYMR) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Medpace (MEDP). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Volatility (1Y, Annualized)	62.83%	44.16%
Beta (5Y)	2.00	1.10
Max Drawdown (5Y)	-83.27%	-42.87%
Avg. Volume (3M)	833.05K	258.39K

Risk-Adjusted Performance

Risk-Return Positioning

KYMR and MEDP are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Sharpe Ratio (1Y)	2.03	0.20
Sortino Ratio (1Y)	4.16	0.26

Profitability

ROE (TTM)

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medpace (MEDP) reports 23.12%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
ROE (TTM)	-27.29%	117.88%
ROA (TTM)	-17.64%	18.71%
Net Margin (TTM)	0.00%	18.24%
Operating Margin (TTM)	-396.04%	23.12%
Gross Margin (TTM)	0.00%	72.24%

Growth

Revenue Growth

Medpace (MEDP) at 19.97% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Revenue Growth (YoY)	-16.70%	19.97%
Revenue Growth (3Y CAGR)	-5.74%	20.12%
EPS Growth (YoY)	--	20.98%
EPS Growth (3Y CAGR)	--	28.04%

Financial Strength

Current Ratio (MRQ)

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Medpace (MEDP) at 0.29 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Current Ratio (MRQ)	11.13	0.83
Debt / Equity (MRQ)	0.05	0.29
Net Debt / EBITDA	--	-0.84

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): KYMR does not report P/E ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Medpace (MEDP) at 6.44 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Kymera Therapeutics (KYMR) vs. Medpace (MEDP): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Medpace (MEDP)
Metric	KYMR	MEDP
P/E Ratio (TTM)	--	36.26
P/S Ratio (TTM)	110.00	6.44
P/B Ratio (MRQ)	6.96	31.23
Free Cash Flow Yield (TTM)	-1.46%	2.72%